Therapeutic antibodies and alternative formats against SARS-CoV-2.

Winiger, Rahel R; Perez, Laurent

Winiger, Rahel R; Perez, Laurent.

Afiliación

Winiger RR; University of Lausanne (UNIL), Lausanne University Hospital (CHUV), Service of Immunology and Allergy, and Center for Human Immunology Lausanne (CHIL), Switzerland. Electronic address: rahel.winiger@chuv.ch.
Perez L; University of Lausanne (UNIL), Lausanne University Hospital (CHUV), Service of Immunology and Allergy, and Center for Human Immunology Lausanne (CHIL), Switzerland. Electronic address: laurent.perez@chuv.ch.

Antiviral Res ; 223: 105820, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38307147

ABSTRACT

ABSTRACT

The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, the virus remains a threat. The ancestor viral strain has evolved into several variants of concern, with the Omicron variant now having many distinct sublineages. Consequently, most available antibodies targeting the spike went obsolete and thus new therapies or therapeutic formats are needed. In this review we focus on antibody targets, provide an overview of the therapeutic progress made so far, describe novel formats being explored, and lessons learned from therapeutic antibodies that can enhance pandemic preparedness.

Asunto(s)

COVID-19; SARS-CoV-2; Humanos; COVID-19/terapia; Pandemias/prevención & control; Anticuerpos

Palabras clave

Antibody; Nanobodies; RBD; SARS-CoV-2; Spike; Viral neutralization

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Antiviral Res Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google